Imperagen Raises £5M for AI-Driven Enzyme Engineering

UK-based biotech innovator Imperagen has successfully closed a £5 million seed funding round, injecting significant capital into its mission to revolutionize enzyme engineering. The investment, spearheaded by PXN Ventures with crucial participation from IQ Capital and Northern Gritstone, will accelerate the company's development of advanced computational methods for designing and optimizing enzymes.

Founded in 2021 by a trio of scientists from the Manchester Institute of Biotechnology, Imperagen is moving beyond traditional, time-intensive laboratory experimentation. The company leverages a sophisticated blend of quantum physics simulations and proprietary AI models to predict enzyme behavior with unprecedented speed and accuracy. This computational approach allows for the exploration of millions of potential enzyme variants, drastically reducing the need for costly and slow physical trial-and-error processes that have long characterized the field.

The core of Imperagen's technology lies in its closed-loop simulation system. Advanced quantum physics modeling identifies promising enzyme modifications, which are then translated into custom-trained AI algorithms. To ensure continuous refinement and real-world applicability, the company employs automated laboratory systems to generate experimental data, feeding it back into the AI models for ongoing learning and improvement. This integrated approach promises to make enzyme development significantly faster, more reliable, and commercially viable.

Enzymes are fundamental biological catalysts with far-reaching applications across numerous industries, including pharmaceuticals, food production, agriculture, and the burgeoning bio-based chemicals sector. The ability to engineer more efficient and specific enzymes can unlock substantial advancements, such as accelerating drug discovery pipelines and enabling more sustainable industrial manufacturing processes. The market for enzyme-based solutions is projected for robust growth, driven by increasing demand for sustainable and bio-based alternatives.

To steer its ambitious growth strategy, Imperagen has appointed Guy Levy-Yurista as its new Chief Executive Officer. With a strong background in AI, life sciences, and enterprise technology, Levy-Yurista is tasked with scaling the company's AI infrastructure for biocatalysis, forging industrial partnerships, and developing commercial models. He highlighted the current limitations of even advanced AI in enzyme engineering, noting that many solutions falter at industrial scale, a challenge Imperagen aims to overcome.

This latest funding brings Imperagen's total raised capital to £8.5 million. The new funds are earmarked for expanding its team of AI specialists, bolstering research and development efforts, enhancing experimental laboratory capabilities, and establishing a robust go-to-market function within the next two years. The company's ultimate vision is to empower industries to produce cleaner, safer, and more effective products, aligning environmental benefits with commercial success.